Inogen, Inc (INGN) Given Consensus Rating of “Buy” by Analysts
Inogen, Inc (NASDAQ:INGN) has received a consensus recommendation of “Buy” from the eight analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $90.80.
INGN has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $108.00 price objective on shares of Inogen in a research note on Friday, September 1st. BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and set a $90.00 price objective on shares of Inogen in a research note on Tuesday, September 12th. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, J P Morgan Chase & Co upped their price objective on Inogen to $102.00 and gave the stock an “overweight” rating in a research note on Monday, June 26th.
Inogen (NASDAQ INGN) opened at 94.78 on Thursday. Inogen has a one year low of $50.24 and a one year high of $105.35. The stock’s 50 day moving average price is $98.16 and its 200 day moving average price is $91.25. The company has a market capitalization of $1.96 billion, a P/E ratio of 82.27 and a beta of 0.99.
Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.25 EPS. Equities analysts anticipate that Inogen will post $1.21 EPS for the current fiscal year.
In related news, EVP Alison Bauerlein sold 15,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $94.93, for a total transaction of $1,423,950.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $92.45, for a total value of $231,125.00. Following the transaction, the executive vice president now directly owns 6,964 shares in the company, valued at $643,821.80. The disclosure for this sale can be found here. Insiders have sold a total of 73,667 shares of company stock valued at $7,041,641 over the last 90 days. 5.31% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. Curbstone Financial Management Corp increased its position in Inogen by 87.9% during the 3rd quarter. Curbstone Financial Management Corp now owns 22,460 shares of the medical technology company’s stock valued at $2,136,000 after buying an additional 10,505 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Inogen during the 2nd quarter valued at about $442,000. Koch Industries Inc. increased its position in Inogen by 19,485.8% during the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after buying an additional 653,747 shares in the last quarter. Verition Fund Management LLC acquired a new position in Inogen during the 2nd quarter valued at about $280,000. Finally, Piedmont Investment Advisors LLC acquired a new position in Inogen during the 2nd quarter valued at about $336,000.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.